ISB News

Six Years In, ISB’s Innovator Award Program an ‘Unqualified Success’ 

Innovator Award Program ROI

Over five completed cycles, the Innovator Award Program has resulted in 16 funded projects, seven patents filed, 22 papers published, 28 new grant ideas, 35 partnerships created, six software products and nine new methods or technologies. 

The fifth cycle of ISB’s Innovator Award Program officially wrapped up this week with the principal investigators of the 2021-22 projects delivering their final presentations. In April, three 2022-23 Innovator Award collaborative projects were announced. (See the full list of current and former Innovator awardees and projects here.)   

“The Innovator Award Program has been an unqualified success,” said Dr. Nitin Baliga, ISB senior vice president, director and professor. “We created this program in 2017 to drive innovation at ISB and to award cross-cutting projects that bring people from different labs together. The Innovators Program also provides training for participants in grant writing, the preparation of project materials, leading teams, managing budgets, and other tasks that are important for transitioning into an independent career,” he said.

The metrics of the program are impressive. Over five completed cycles, the Innovator Award Program has resulted in 16 funded projects, seven patents filed, 22 papers published, 28 new grant ideas, 35 partnerships created, six software products and nine new methods or technologies. 

In 2021, Washington Research Foundation (WRF) pledged $100,000 to ISB to fund the Innovator Award Program, with ISB securing an additional $50,000 from other sources. WRF matched their pledge for the 2022-23 Innovator Award cycle, as well. 

“We thank WRF for their generous support not only for this program, but for their longtime support of ISB,” Baliga said.

WRF has provided more than $2.7 million in grants and pledges, including support that brought microbiome specialist Dr. Sean Gibbons to ISB in 2018.

Learn more about the program here.

The 2021-22 Innovators final presentations were:

Project: Discerning the combinatorial regulatory circuitry of microglial differentiation in Alzheimer’s disease using probabilistic Boolean networks

Lead investigator: Bahar Tercan, Postdoctoral Fellow (Shmulevich lab)

ISB research team and collaborators: Cory Funk (Hood-Price Lab), Boris Aguilar (Shmulevich Lab) and Max Robinson (Hood-Price Lab)

 

Project: SOMA: Joint spatial omics and metabolic function analysis in single tissue section at single cell sensitivity

Lead investigator: Yin Tang, Postdoctoral Fellow (Wei Lab)

ISB research team and collaborators: Guangrong Qin (Shmulevich Lab), David L. Gibbs (Shmulevich Lab), Hanjun Cheng (Wei Lab) and Xiaoyang Ye (Wei Lab)

External collaborator: Raymond S. Yeung, University of Washington

 

Project: Multiparameter profiling of exosomes from body fluids to detect and determine site of infection

Co-lead investigators: Yue Lu, Postdoctoral Fellow (Heath Lab) and Christopher Lausted (Hood-Price Lab)

ISB research team and collaborators: Kai Wang (Hood-Price Lab), Alphonsus Ng (Heath lab) and Inyoul Lee (Hood-Price Lab)

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.